Openly accessible

Aptamers and glioblastoma: their potential use for imaging and therapeutic applications

Hays, Emma M, Duan, Wei and Shigdar, Sarah 2017, Aptamers and glioblastoma: their potential use for imaging and therapeutic applications, International journal of molecular sciences, vol. 18, no. 12, pp. 1-17, doi: 10.3390/ijms18122576.

Attached Files
Name Description MIMEType Size Downloads
hays-aptamersandglioblastoma-2017.pdf Published version application/pdf 994.52KB 1

Title Aptamers and glioblastoma: their potential use for imaging and therapeutic applications
Author(s) Hays, Emma M
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Shigdar, SarahORCID iD for Shigdar, Sarah orcid.org/0000-0001-8084-8447
Journal name International journal of molecular sciences
Volume number 18
Issue number 12
Article ID 2576
Start page 1
End page 17
Total pages 17
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2017-11-30
ISSN 1422-0067
Keyword(s) SELEX
aptamers
biomarkers
blood brain barrier
cancer
diagnosis
glioblastoma
imaging
targeted therapies
science & technology
life sciences & biomedicine
physical sciences
biochemistry & molecular biology
chemistry, multidisciplinary
chemistry
Summary Glioblastoma is a highly aggressive primary brain tumour, renowned for its infiltrative growth and varied genetic profiles. The current treatment options are insufficient, and their off-target effects greatly reduce patient quality of life. The major challenge in improving glioblastoma diagnosis and treatment involves the development of a targeted imaging and drug delivery platform, capable of circumventing the blood brain barrier and specifically targeting glioblastoma tumours. The unique properties of aptamers demonstrate their capability of bridging the gap to the development of successful diagnosis and treatment options, where antibodies have previously failed. Aptamers possess many characteristics that make them an ideal novel imaging and therapeutic agent for the treatment of glioblastoma and other brain malignancies, and are likely to provide patients with a better standard of care and improved quality of life. Their target sensitivity, selective nature, ease of modification and low immunogenicity make them an ideal drug-delivery platform. This review article summarises the aptamers previously generated against glioblastoma cells or its identified biomarkers, and their potential application in diagnosis and therapeutic targeting of glioblastoma tumours.
Language eng
DOI 10.3390/ijms18122576
Field of Research 0399 Other Chemical Sciences
0604 Genetics
0699 Other Biological Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2017, the authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30109002

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 10 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Tue, 05 Jun 2018, 10:48:04 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.